# Introduction

Obesity is a chronic disease that affects approximately 40% of the American population (13). The disease is characterized by excess adipose tissue that can lead to glucose and lipid dysregulation (20). Obesity increases the risk of type 2 diabetes, hypertension and insulin resistance among other chronic diseases (17). Those affected by obesity also may have reduced capacity to exercise thereby exacerbating these health issues (19) Contractile function of skeletal muscle and muscle performance is also reduced in obese persons which can overall lead to reduced mobility (44).

Skeletal muscle is vital to normal function and to the maintenance of health. Muscle is central to the regulation of lipid, glucose and amino acid concentrations , processes which are commonly dysregulated during times of illness or disease (50). However, many factors including age, poor nutrition, lack of exercise, medication, and diseases can lead to loss of skeletal muscle and function, with attendant reductions in lifespan and health-span (24). One causal factor in muscle loss is elevated glucocorticoids.

Glucocorticoids are steroid hormones that function through the Glucocorticoid Receptor (GR, encoded by the *Nr3c1* gene) to alter tissue-specific gene expression (32). Exogenous glucocorticoids induce muscle atrophy through increased muscle proteolysis and inhibition of protein synthesis in lean mice (18, 40). The estimated prevalence of oral glucocorticoids usage in the United States is 1-2%, normally prescribed for health concerns including asthma, chronic obstructive pulmonary disease, and a range of autoimmune disorders (31). Glucocorticoids are also elevated during chronic stress or fasting (9, 46). Elevated levels of glucocorticoids within the human body have shown to cause skeletal muscle atrophy (5, 23, 32, 40). This muscle atrophy stems from an upregulation of atrogenes and other factors which promote muscle protein breakdown (33, 38, 40).

Muscle proteolysis is in part caused by glucocorticoid induction of atrogenes, a set of E3 Ubiquitin ligases including MuRF1 and Atrogin-1, downstream of the FOXO pathway (21, 39). These E3 ligases target muscle proteins for degradation, primarily to provide substrates for gluconeogenesis. The inhibition of protein synthesis by glucocorticoids is believed to be directed by inhibition of the mTORC1 pathway (40).

Work from our group and others have demonstrated that glucocorticoid action is altered in obese rodents, including changes in adipocyte gene transcription, lipolysis, glucose production and insulin resistance in obese, relative to lean animals (2, 8, 14, 18, 43). In this thesis, I demonstrate that both lean and obese mice develop reductions in lean mass, muscle mass, and grip strength when treated with dexamethasone and these effects are increased in obese mice. I also show that obese, dexamethasone treated mice had transient induction key transcripts including *Fbxo32* and *Trim63*, (Atrogin-1 and MuRF1 respectively) and their upstream regulator *Foxo3*. Lastly, I will show the obese dexamethasone-treated mice are profoundly insulin resistant, even after accounting for reductions in muscle mass.

# Methods

## Animal Husbandry

Male C57BL/6J mice were purchased from The Jackson Laboratory at nine weeks of age and randomized into groups of four animals/cage. All animals were on a light/dark cycle of 12 hours and housed at 22°C. At 10 weeks of age, mice were placed on a high-fat diet (HFD; 45% fat from lard, 35% carbohydrate mix of starch, maltodextrin, and sucrose, and 20% protein from casein, Research Diets cat no. D12451) or kept on a normal chow diet (NCD; 13% fat, 57% carbohydrate, and 30% protein; Teklad catalog no. 5LOD) for 12 weeks. At 22 weeks, mice were either treated with vehicle (water) or 1 mg/kg/d of dexamethasone (Sigma-Aldrich; catalog no. 2915) dissolved in their drinking water. All mice were provided with *ad libitum* access to food and their respective waters throughout the study. Food and liquid consumption were measured weekly to determine the concentration of dexamethasone consumed per cage and volumes were averaged per mouse per cage. All animal procedures were approved by the University of Michigan or University of Tennessee Health Sciences Center Institutional Animal Use and Care Committees.

## Grip Strength

Mice were tested using a grip strength meter with a Chatillon digital force gauge (AMETEK). These mice were treated for six weeks with their respective waters. A grip strength baseline was established per mouse and all measurements were reported in force (N). Mice were placed on a grid attached to the meter and once all four paws had contact with the grid, the mice were slowly pulled backwards by the tail until they left the grid. Each mouse was tested five times and given approximately 10 seconds rest in between each test. Final measurements for grip strength were assessed by taking the average of the five trials and reported as average peak force (N).

## Contractile Measurements

All contractile properties were measured for gastrocnemius muscles *in situ*. After the mouse was anesthetized using isoflurance, the right gastrocnemius muscle was carefully isolated and a 4–0 silk suture was tied around the distal tendon. After the tendon was secured, the tendon was cut so the hindlimb could be secured at the knee to a fixed post. Animals were placed on a temperature-controlled platform with continual drip of saline over the gastrocnemius at 37°C to keep with muscle warm and moist. The distal tendon of the gastrocnemius muscle was tied to the lever arm of a servomotor (6650LR, Cambridge Technology). In order to measure force generated at the nerve, a bipolar platinum wire electrode was used to stimulate the muscle at the tibial nerve.

The voltage of the electrode pulses was incrementally adjusted to find maximum isometric twitch and the muscle length was altered to find the optimal length (Lo). Optimal length is the length of the muscle in which the maximal twitch force was obtained. Once Lo was found, gastrocnemius muscles were kept at that length (Lo) and the frequency of pulses was increased in increments of 300-ms to obtain maximum isometric tetanic force (Po). In order to measure force generated at the muscle, an electrode cuff was placed around the mid-belly of gastrocnemius for muscle stimulation. The process was then repeated as done for the nerve.

After all force measurements, both gastrocnemius and quadricep muscles were dissected, weighed, and snap frozen in liquid nitrogen. Mice were sacrificed under anesthesia via removal of vital organs and muscles were stored at -80°C.

## Histology and Fiber Type Quantifications

Quadriceps were collected and frozen in 2-methyl-butane cooled under liquid nitrogen. Quadricep samples were sectioned using a CryoStar NX350 HOVP Cryostat (Thermo Scientific) at -20°C with a thickness of 10um through the mid-belly and mounted on SuperFrost glass slides (Electron Microscopy Sciences, catalog no. 71882-01). For analysis of fiber cross-sectional area (CSA), fibers were assessed by hematoxylin and eosin (H&E staining) and for fiber-type, muscles were stained using NADH-NBT staining as described in (15, 42). Light-stained fibers were labeled as Type IIb fibers, medium-stained fibers as Type IIa and dark-stained as Type I fibers. Each section of mouse quadricep was imaged in four times; topleft, topright, bottom-left and bottom right photos were taken. The images were taken using a 20x objective of an EVOS XL digital inverted microscope. Muscle fibers were individually counted in each image and the cross-sectional area was measured by outlining 150 randomly chosen fibers per image and using ImageJ (4).

## Cell Culture

C2C12 cells, a immortalized mouse skeletal muscle cell line, were cultured in 10% Fetal Bovine Serum (FBS), Dulbecco's Modification of Eagle's Medium (DMEM; 4.5 g/L D- glucose; Fisher Scientific; catalog no.11965118) with penicillin, streptomycin and glutamine (PSG). Cells were split at approximately 75% confluency and differentiated using DMEM, 1x PSG with 2% Horse serum until myotubes were obtained. Media was replenished as needed until myotube differentiation was complete around one week. Myotubes were treated with 250 nM dexamethasone for either 2, 4, 8, 12, or 24 hours or left untreated. All cells were kept in a 5% CO2 regulated incubator at 37 °C. After treatment, cells were homogenized in TRIZol using a TissueLyser II (Qiagen) and prepared for RNA extraction using a PureLink RNA kit (Life Technologies, cat no.12183025).

## mRNA Quantification

Cells and tissues were lysed in TRIzol using a TissueLyser II (Qiagen) and RNA was extracted using a PureLink RNA kit (catalog no. 12183025; Life Technologies) following manufacturer’s instructions. Complementary DNA (cDNA) was synthesized using the High Capacity cDNA Reverse Transcription Kit without RNAse inhibitor (catalog no. 4368813; Life Technologies). Quantitative Real-Time Polymerase Chain reaction (qPCR) was performed using a QuantStudio 5 (Thermo Fisher Scientific) with primers, complementary DNA, and Power SYBR Green PCR Master Mix (catalog no. 4368708; Life Technologies) per manufacturer’s instructions. Messenger RNA (mRNA) expression levels were normalized to control gene, *Rplp13*, and analyzed (Table 1).

Assessment of Insulin Tolerance

Insulin tolerance testing took place between ZT8 and ZT10 following a 6-hour fast. Mice were assessed for glucose levels using a handheld glucometer (Accu-chek) with blood drawn from the tail vein. Insulin (Humulin R, Lilly) was then administered at 0.75IU per kg of lean mass with lean mice determined by MRI and 1.5IU per kg of lean mass for obese mice via intraperitoneal injection (14). Glucose was measured in 15 minutes intervals for a total of two hours following insulin administration.

## Body, Fat, and Lean Mass Determination

Body weight was measured using a digital scale. The animal’s fat and lean mass were determined weekly using a EchoMRI 2100 (EchoMRI). Mice were placed in plastic holding tube without sedation or anesthesia. The holder was then inserted into the EchoMRI machine.

## Statistics

All results are represented as mean ± SEM. Two-Way ANOVA analyses, mixed linear models and Chi-squared tests were performed to test for significance and determine interactions between diet and dexamethasone treatment. Pairwise testing was performed after assessing normality and equal of variances. If Shapiro-Wilk test was insignificant, a Levene’s tests was performed and followed by either a Welch’s or Student’s *t*-test as noted in the figure legends. Any p-value under 0.05 was considered significant. All statistical tests were conducted using R version 3.5.0 (35).

# Results

In order to assess diet-induced obesity in mice, randomized mice into diets of chow or high fat diet. To assess weight gain, I measured weekly body mass, fat mass, and food intake. NCD animals treated with vehicle (water) had larger body weights and fat mass compared to dexamethasone-treated counterparts. This pattern was consistent in HFD animals as well. HFD animals had approximately the same percent body fat mass at 30% (Table 1). I also evaluated food intake during the course of treatment to determine the possible origin of changes in adiposity. I measured weekly food consumption and found that average food intake per mouse per day was approximately the same for each treatment group regardless of chow-type except for the HFD-water animals. However, the HFD-water animals ate approximately the same as NCD animals while HFD-dexamethasone animals consumed approximately 70% more calories per day. Though HFD dexamethasone mice ate the most calories, they lost fat mass when compared to their HFD counterparts(Table 1).

To determine the dosage of dexamethasone treatment the mice were receiving, I measured their weekly water intake. HFD animals receiving dexamethasone water drank approximately 4mL more water or receieved 0.2 mg more dexamethasone than their lean-dexamethasone counterparts. These findings are consistent with prior data seen in the Bridges lab(14).

## Greater Losses in Grip Strength in Obese-Dexamethasone Mice

As a test to assess the effect of glucocorticoids on muscle strength, we treated lean and obese male mice with dexamethasone for five weeks and measured grip strength. Dexamethasone treatment resulted in reductions in grip strength in both lean and obese mice when compared to their counterparts (Figure 1A-B). Obese dexamethasone-treated mice had greater overall losses in grip strength when compared to the lean animals. For mean grip strength, we saw a 4.8% reduction in lean animals (p=0.007) but a 26.2% reduction in grip strength for obese animals (p=3.6x10-5).

## Reductions in Strength are Related to Smaller CSA

In order to expand upon these results, we measured the force generated by gastrocnemius muscle *in situ* both by stimulation of the nerve and by direct electrical stimulation of the muscle. In NCD animals, the force generated by nerve stimulation was reduced 10.2% when treated with dexamethasone. However, in HFD animals force generated by nerve stimulation was reduced 32.2% when treated with dexamethasone, with a significant interaction between pre-existing obesity and dexamethasone treatment (p=.009 Figure 1C). These results are concordant with results from direct muscle stimulation. In NCD animals, force generated by direct muscle stimulation was reduced 10.6% when treated with dexamethasone, while in HFD animals, the force generated by direct muscle stimulation was reduced 30.2% when treated with dexamethasone (pinteraction=0.024, Figure 1D).

In order to examine whether changes in muscle strength were proportional to declines in muscle size, I plotted a regression of force (mN) versus whole-muscle cross-sectional area (CSA). The cross-sectional area explained 64% and 59% of the variance in force stimulated at the nerve and muscle respectively. As cross-sectional area declined muscle force by both stimulations decreased in proportion. Pre-existing obesity did not modify this force-area relationship (Nerve Stimulation: p=0.47, Muscle Stimulation: p=0.42). These data indicate that pre-existing obesity causes more dramatic dexamethasone-induced muscle weakness, but this is largely explained by reductions in muscle size.

## Enhanced Muscle Loss in Obese Mice

To determine whether obesity and glucocorticoid treatment promoted losses in muscle mass, we treated lean and obese male mice with dexamethasone for five weeks. Dexamethasone caused a reduction in lean mass in both lean and obese mice. Consistent with losses in strength, obese-dexamethasone treated mice had greater losses in lean mass (pinteraction = 6.3x10-14; Figure 2A). This loss in lean mass is consistent with previously reported effects of glucocorticoids on muscle atrophy (34) (39). At sacrifice, the NCD animals quadricep and triceps surae weights were smaller by 18% and 12% in the dexamethasone treated. While in HFD animals, quadricep and tricep surae weights were smaller by 42% and 33% in the dexamethasone treated mice (for quadriceps pinteraction = 1.5×10-5; for tricep surae pinteraction = 0.0030 Figure 2B).

I next evaluated short-term dexamethasone treated animals by placing male mice on vehicle or dexamethasone for two weeks to match our isometric force testing. The obese, dexamethasone-treated animals had enhanced reductions gastrocnemius weights and whole-muscle cross-sectional area (Figure 2C-D). At sacrifice, the NCD animals’ gastrocnemius weights were smaller by 13% in the dexamethasone treated group but 27% in the HFD group (pinteraction=0.021). Similarly, cross-sectional area of the muscle was reduced 13% in the NCD group and 23% in the HFD group though the modifying effect of obesity did not statistical significance (pinteraction=.11).

## Obesity with Dexamethasone Treatment Resulted in Smaller Muscle Fibers

In order to assess changes at the individual muscle fiber-level, I cryosectioned the 5-week dexamethasone-treated mice quadriceps at the mid-belly and H&E stained these samples (Figure 2E). The NCD animal’s muscle fibers were smaller by 17% in the dexamethasone treated and in HFD animals muscle fibers were smaller by 55% in the dexamethasone treated mice (pinteraction=.0010; Figure 2F).

## Dexamethasone did not Induce Changes in Fiber-Type Composition

In order to assess any changes in the ratio of oxidative versus non-oxidative fiber-types, I stained muscle sections and quantified the muscle fibers based upon their oxidative capacity. Mouse skeletal muscle is made up Type I, Type IIa, Type IIb, and Type IIx fibers (41, 42). Oxidative fibers or Type I fibers stain the darkest (Figure 2G). I found no significant change in the ratio of oxidative to total fibers in the mice quadriceps in lean or obese mice treated with dexamethasone (Figure 2H).

## Dexamethasone Reduced Type II Fiber Cross-Sectional Area

Though I did not see changes in composition of fiber types, I did observe fiber-type specific reductions in fiber size. Dexamethasone-treatment reduced Type IIa or light-stained fibers CSA in lean and obese mice by 28% and 40% respectively though the moderating effect of obesity did not reach statistical reference (pinteraction=0.49). Dexamethasone treatment also reduced Type IIb or medium-stained fibers CSA in lean and obese by 35% and 32% respectively (pinteraction=0.58). As for Type I or dark-stained fibers, dexamethasone treatment only reduced fiber CSA in NCD animals. Though dexamethasone treatment reduced Type I fiber CSA by 21% in lean, the treatment increased fiber CSA in obese mice by 14% (pinteraction=p=0.0031; Figure 2I). This outcome is consistent with previous reports of plantaris muscles from mice treated with dexamethasone for 13 days that showed significant atrophy in Type IIb and Type IIa but not in Type I fibers (37).

## Short-term Dexamethasone-Treatment Induced Muscle Degradation Transcripts as seen *in vitro*

It is well established that dexamethasone treatment induces expression of muscle atrophy-related genes (21, 38, 47). To better understand these cell-autonomous effects, I treated C2C12 myotubes with dexamethasone over time in order to assess the expression of *Foxo1*, *Foxo3*, and the atrogenes, MuRF1 and Atrogin-1 (encoded by *Trim63* and *Fbxo32* respectively)*.* Relative expression of all genes were elevated after 2 hours of treatment with dexamethasone (Figure 3A).

To evaluate the molecular effects of dexamethasone *in vivo* and how this was moderated by obesity, I treated lean and obese mice with dexamethasone and evaluated atrogene expression in quadriceps. After one week of dexamethasone treatment, we observed a greater induction of both *Foxo3* and the atrogenes, *Trim63* and *Fbxo32*, in obese mice as compared to their lean counterparts though the interaction between obesity status and dexamethasone treatment did not reach statistical significance for these transcripts (Figure 3B). The expression of *Trim63, Fbxo32,* and *Foxo3* was elevated in obese mice than their lean counterparts*.* However, I did not observe a dexamethasone-induced increase in *Foxo1* or *Ncr31*, glucocorticoid receptor. These data suggest that the obesity-sensitizing effects on muscle atrophy could be related to elevations of FOXO3 and these two atrogenes.

### Obese Dexamethasone-Treated Mice are Insulin Resistant

Since I have established that obesity can enhance steroid-induced skeletal muscle atrophy, I next evaluated insulin resistance as the majority of all postprandial glucose uptake occurs within the muscle (10). In lean animals, there was no significant change in fasting blood glucose with a reduction of 6.2% between treatment groups however there was a 44% increase in fasting blood glucose in obese animals given dexamethasone (pinteraction=0.033; Figure 4A), consistent with our previous report (14).

In order to evaluate whether the dexamethasone-treated animals were insulin resistant, I treated lean and obese mice with insulin at doses relative to their fat-free mass. This was to account for their difference in muscle mass between dexamethasone treated and control mice. In both NCD and HFD animals, dexamethasone induced near complete insulin resistance (p= 8.8 x 10-12 for NCD and 7.7 x 10-7 for HFD; Figure 4B). Notably HFD mice and NCD mice were given different doses of insulin, so that near-equivalent insulin responses could be observed. These data suggest that even after accounting for change in muscle mass, glucocorticoids still cause insulin resistance.

# Discussion

Here I demonstrate that dexamethasone treatment in concert with pre-existing obesity caused elevated reductions in muscle strength, size and insulin sensitivity in mice. Muscle weakness is a common side effect of exogenous glucocorticoid consumption as well as continually elevated levels of endogenous glucocorticoids (12, 40). For example, adults who had elevated salivary cortisol had a significantly higher risk of loss of grip strength than their peers (32). My research could be particularly important because those with obesity are more likely to have reduced muscle function (1, 19, 28, 51). Notably people with obesity are also more likely to have elevations in endogenous glucocorticoid levels (36, 48).

I chose to look at exogenous glucocorticoid treatment in the form of dexamethasone, a fluorinated synthetic glucocorticoid. Mice were given *ad libitum* access to 1 mg/kg/d of dexamethasone dissolved in their drinking water. This quantity of dexamethasone treatment is equivalent to a human dose of 0.081 mg/kg/d, which is comparable to a high therapeutic dose administered to human patients which usually can range from 0.002-0.2mg/kg/d (3, 25, 27, 29) Our data agrees with prior research in the Bridges Lab has shown that obese mice drank more dexamethasone water, therefore this is a limitation to our findings(14). Obese dexamethasone treated mice may be receiving a larger dose than non-obese mice resulting in more glucocorticoid action in the mice and greater muscle atrophy.

In addition to steroid-induced atrophy, there are a variety of conditions and lifestyle factors such a bed-rest that also lead to other significant myofiber changes. For instance, disuse atrophy as a result of denervation or immobilization of a limb, reduces Type I fiber size and muscle mass (30, 37, 45). Because I found an effect on obesity on glucorticoid-induced muscle atrophy, further research about whether other forms of muscle loss are moderated by obesity is warranted.

I observed no change in fiber-type composition in response to treatment with dexamethasone, while other studies have shown that dexamethasone reduces both the proportion and size of Type II fibers in muscles in rats (5, 23). This discrepancy could be due to that fact that these studies are done in rats and not mice. The discrepancy could also be due to the fiber composition of the muscles they chose to evaluate, gastrocnemius and flexor digitorum superficialis combined, compared to our examination of the quadriceps.

It is also important to note that glucocorticoids induce muscle atrophy in a muscle specific manner. Researchers often test mouse hindlimb muscles because they are fairly large and accessible load bearing muscles. They also include muscles with prominent proximal and distal tendons allowing for attachment to equipment to measure force. Specifically, Type II fibers are more prone to the effect of glucocorticoids (5, 12, 23, 37, 40) so it is possible that muscles with higher concentrations of Type II fibers may be more vulnerable to obesity and steroid-induced atrophy. The mechanism by which glucocorticoids target Type II muscle fibers is unknown (40). It is possible that glucocorticoids preferentially target fibers that have lower activity levels or fiber that have more dense sarcoplasmic reticulums (6, 7) For example, rats treated with dexamethasone for two weeks had no significant reduction in mean fiber CSA in their soleus muscles but had significant reductions in their plantaris muscles, which have higher Type II fiber composition (37). It is plausible that a loss in non-oxidative fibers could reduce a human’s ability to use short bursts of energy or lifting heavy objects (49).

How this increased responsiveness to dexamethasone in obese animals occurs is not currently clear. One possibility is that obesity remodels the chromatin landscape, allowing for easier GR access. Obesity alters the packing and accessibility of DNA in adipocytes. (14, 18, 22) Obesity may have a similar effect in muscle in which Glucocorticoid Response Elements or other transcription factors may more easily bind to receptors causing increased glucocorticoid action. Another theory is that the effects of GR-dependent signaling is promoted by insulin resistance. Obesity is shown to promote insulin resistance therefore it is not unimportant to consider that the GR would act as if the body is starved of glucose and induce a cycle of muscle breakdown. It may also be a combination of these two ideas in which drugs could directly affect chromatin remodeling thereby increasing insulin sensitivity (22)

A final possible theory is that first excess adipose tissue contributes pro-inflammatory cytokines that act upon skeletal muscle and then as an additive effect, glucocorticoids function to increase skeletal muscle degradation. Pro-inflammatory cytokines have catabolic effects on protein metabolism and anabolic effects such as reduced *de novo* protein synthesis. Tumor necrosis factor alpha has been shown to directly act on muscle cells to induce protein degradation in C2C12 myotubes (26). It is possible that excess adiposity could sensitize muscles to degradation and glucocorticoids function as a second-hit of catabolism, which would lead to exacerbated muscle weakness (11).

Glucocorticoids and obesity both have deleterious health effects. These effects include loss of skeletal muscle which may result in reduced motor function, coordination, and energy production (19, 28, 51). Insulin resistance is an additional negative effect associated with both elevated glucocorticoids and excess adiposity in the body (14, 16, 33). The process by which these factors induce insulin resistance is not yet fully understood. In this study, I have highlighted that dexamethasone-induced muscle atrophy is exacerbated in an obese mouse model, as evidenced by synergistic reductions in muscle function, muscle mass, and fiber-specific cross-sectional area.

# Funding Sources

This work was supported by the Walter Block Scholarship and the Nutritional Sciences Dean’s Award (LG), R01DK017535 (DB), a pilot and feasibility grant from the Michigan Diabetes Research Center (P30DK020572 to DB) and the Functional Assessment Core of the Michigan Integrative Musculoskeletal Health Core Center (P30AR069620).

# Acknowledgements

I would like to acknowledge my Principal Investigator, Dr. Dave Bridges, for his guidance and dedication to this research and my degree completion. I would also like to recognize my lab mentors; Innocence Harvey and JeAnna Redd, for teaching me new lab techniques and tirelessly helping me complete my daily tasks. A big “thank you” to my collaborator, Dr. Susan V. Brooks and her right-hand woman, Carol Davis, whom dealt with me for many hours while muscle testing. Also shout out to my new friends at the BSRB, for teaching me about mouse muscles, Dr. Pete Macpherson and Dr. James Markworth. Lastly I would like to thank some members of the Bridges Lab including Ayat AL-Tamimi, Molly Carter, Noura El Habbal, and Detrick Snyder for their friendship, support, and assistance in mouse work.

# References

1. **Abdelmoula A**, **Martin V**, **Bouchant A**, **Walrand S**, **Lavet C**, **Taillardat M**, **Maffiuletti NA**, **Boisseau N**, **Duché P**, **Ratel S**. Knee extension strength in obese and nonobese male adolescents. *Appl Physiol Nutr Metab* 37: 269–75, 2012.

2. **Beaudry JL**, **D’souza AM**, **Teich T**, **Tsushima R**, **Riddell MC**. Exogenous glucocorticoids and a high-fat diet cause severe hyperglycemia and hyperinsulinemia and limit islet glucose responsiveness in young male Sprague-Dawley rats. *Endocrinology* 154: 3197–3208, 2013.

3. **Becker DE**. Basic and Clinical Pharmacology of Glucocorticosteroids. *Anesth Prog* 60: 25–32, 2013.

4. **Bergmeister KD**, **Gröger M**, **Aman M**, **Willensdorfer A**, **Manzano-Szalai K**, **Salminger S**, **Aszmann OC**. Automated muscle fiber type population analysis with ImageJ of whole rat muscles using rapid myosin heavy chain immunohistochemistry. *Muscle and Nerve* 54: 292–299, 2016.

5. **Bhasin S**, **Artaza J**, **Mahabadi V**, **Mallidis C**, **Ma K**, **Gonzalez-Cadavid N**, **Arias J**, **Salehian B**. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. *Am J Physiol Metab* 285: E363–E371, 2015.

6. **Bodine SC**, **Furlow JD**. Glucocorticoid Signaling. New York, NY: Springer New York, 2015.

7. **Chen D**, **Yang MR**, **Huang LN**, **Qiu YW**, **Li ST**. Dexamethasone-induced hyposensitivity to rocuronium in rat diaphragm associated with muscle-fiber transformation. *Mol Med Rep* 9: 527–534, 2014.

8. **D’souza AM**, **Beaudry JL**, **Szigiato AA**, **Trumble SJ**, **Snook LA**, **Bonen A**, **Giacca A**, **Riddell MC**. Consumption of a high-fat diet rapidly exacerbates the development of fatty liver disease that occurs with chronically elevated glucocorticoids. *AJP Gastrointest Liver Physiol* 302: G850–G863, 2012.

9. **Dallman MF**, **Pecoraro NC**, **La Fleur SE**, **Warne JP**, **Ginsberg AB**, **Akana SF**, **Laugero KC**, **Houshyar H**, **Strack AM**, **Bhatnagar S**, **Bell ME**. Chapter 4: Glucocorticoids, chronic stress, and obesity. *Prog Brain Res* 153: 75–105, 2006.

10. **DeFronzo RA**. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. *Diabetes* 37: 667–687, 1988.

11. **Dey, A; Hao, S.; Erion, J.R.; Wosiski-Kuhn, M.; Stranahan AM**. Glucocorticoid sensitization of microglia in a genetic mouse model of obesity and diabetes. *J Neuroimmunol* 269: 20–27, 2015.

12. **Falduto MT**, **Czerwinski SM**, **Hickson RC**. Glucocorticoid-induced muscle atrophy prevention by exercise in fast-twitch fibers. *J Appl Physiol* 69: 1058–1062, 2017.

13. **Flegal KM**, **Kruszon-Moran D**, **Carroll MD**, **Fryar CD**, **Ogden CL**. Trends in Obesity Among Adults in the United States, 2005 to 2014. *JAMA* 315: 2284, 2016.

14. **Harvey I**, **Stephenson EJ**, **Redd JR**, **Tran QT**, **Hochberg I**, **Qi N**, **Bridges D**. Glucocorticoid-Induced Metabolic Disturbances Are Exacerbated in Obese Male Mice. *Endocrinology* 159: 2275–2287, 2018.

15. **Hebling A**, **Scabora JE**, **Esquisatto MAM**. Muscle Fibre Types and Connective Tissue Morphometry in Frontal Muscle of Norfolk Rabbits (Oryctolagus cuniculus). *Int J Morphol* 27: 187–191, 2009.

16. **Heller EA**, **Cates HM**, **Peña CJ**, **Herman JP**, **Walsh JJ**. Mechanisms of Glucocorticoid-Induced Insulin Resistance: Focus on Adipose Tissue Function and Lipid Metabolism. 17: 1720–1727, 2015.

17. **Heymsfield SB**, **Wadden TA**. Mechanisms, Pathophysiology, and Management of Obesity. *N Engl J Med* 376: 254–266, 2017.

18. **Hochberg I**, **Harvey I**, **Tran QT**, **Stephenson EJ**, **Barkan AL**, **Saltiel AR**, **Chandler WF**, **Bridges D**. Gene expression changes in subcutaneous adipose tissue due to Cushing’s disease. *J Mol Endocrinol* 55: 81–94, 2015.

19. **Hulens M**, **Vansant G**, **Lysens R**, **Claessens AL**, **Muls E**. Exercise capacity in lean versus obese women. *Scand J Med Sci Sport* 11: 305–309, 2001.

20. **Jung UJ**, **Choi MS**. Obesity and its metabolic complications: The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. *Int J Mol Sci* 15: 6184–6223, 2014.

21. **Kang S-H**, **Lee H-A**, **Kim M**, **Lee E**, **Sohn UD**, **Kim I**. Forkhead box O3 plays a role in skeletal muscle atrophy through expression of E3 ubiquitin ligases MuRF-1 and atrogin-1 in Cushing’s syndrome. *Am J Physiol Metab* 312: E495–E507, 2017.

22. **Kang S**, **Tsai LT-Y**, **Rosen ED**. Nuclear Mechanisms of Insulin Resistance. *Trends Cell Biol* 26: 341–351, 2016.

23. **Kelly, Frank J and Goldspink DF**. The differing responses of four muscle types to dexamethasone treatment in the the Rat. *Biochem* 175: 147–151, 1982.

24. **LECKER SH**, **JAGOE RT**, **GILBERT A**, **GOMES M**, **BARACOS V**, **BAILEY J**, **PRICE SR**, **MITCH WE**, **GOLDBERG AL**. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. *FASEB J* 18: 39–51, 2004.

25. **Levitan RD**, **Vaccarino FJ**, **Brown GM**, **Kennedy SH**. Low-dose dexamethasone challenge in women with atypical major depression: Pilot study. *J Psychiatry Neurosci* 27: 47–51, 2002.

26. **Li Y-P**, **Reid MB**. NF-κB mediates the protein loss induced by TNF-α in differentiated skeletal muscle myotubes. *Am J Physiol Integr Comp Physiol* 279: R1165–R1170, 2017.

27. **Lopes MW**, **Leal RB**, **Guarnieri R**, **Schwarzbold ML**, **Hoeller A**, **Diaz AP**, **Boos GL**, **Lin K**, **Linhares MN**, **Nunes JC**, **Quevedo J**, **Bortolotto ZA**, **Markowitsch HJ**, **Lightman SL**, **Walz R**. A single high dose of dexamethasone affects the phosphorylation state of glutamate AMPA receptors in the human limbic system. *Transl Psychiatry* 6, 2016.

28. **Maffiuletti NA**, **Jubeau M**, **Munzinger U**, **Bizzini M**, **Agosti F**, **De Col A**, **Lafortuna CL**, **Sartorio A**. Differences in quadriceps muscle strength and fatigue between lean and obese subjects. *Eur J Appl Physiol* 101: 51–59, 2007.

29. **Nair AB**, **Jacob S**. A simple practice guide for dose conversion between animals and human. *J Basic Clin Pharm* 7: 27, 2016.

30. **Nicks DK**, **Beneke WM**, **Key RM**, **Timson BF**. Muscle fibre size and number following immobilisation atrophy. *J Anat* 163: 1–5, 1989.

31. **Overman RA**, **Yeh JY**, **Deal CL**. Prevalence of oral glucocorticoid usage in the United States: A general population perspective. *Arthritis Care Res* 65: 294–298, 2013.

32. **Peeters GMEE**, **Van Schoor NM**, **Van Rossum EFC**, **Visser M**, **Lips P**. The relationship between cortisol, muscle mass and muscle strength in older persons and the role of genetic variations in the glucocorticoid receptor. *Clin Endocrinol (Oxf)* 69: 673–682, 2008.

33. **Pereira RMR**, **Freire de Carvalho J**. Glucocorticoid-induced myopathy. *Jt Bone Spine* 78: 41–44, 2011.

34. **Pleasure DE**, **Walsh GO**, **Engel WK**, **Pleasure DE**, **Walsh GO**, **Engel W**. ATrophy of skeletal muscle in patients with cushing’s syndrome. *Arch Neurol* 22: 118–125, 1970.

35. **R Core Team**. R: A Language and Environment for Statistical Computing. .

36. **Rosmond R**, **Chagnon YCC**, **Chagnon M**, **Pe L**, **Chagnon M**, **Russe LPE**, **Carlsson RN**, **Lindell K**, **Holm G**, **Chagnon M**, **Pérusse L**, **Lindell K**, **Carlsson B**, **Bouchard C**, **Björntorp P**. A glucocorticoid receptor gene marker is associated with abdominal obesity, leptin, and dysregulation of the hypothalamic-pituitary-adrenal axis. *Obes Res* 8: 211–8, 2000.

37. **Rouleau G**, **Karpati G**, **Carpenter S**, **Soza M**, **Prescott S**, **Holland P**. Glucocorticoid excess induces preferential depletion of myosin in denervated skeletal muscle fibers. *Muscle Nerve* 10: 428–438, 1987.

38. **Sandri M**, **Sandri C**, **Gilbert A**, **Skurk C**, **Calabria E**, **Picard A**, **Walsh K**, **Schiaffino S**, **Lecker SH**, **Goldberg AL**. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. *Cell* 117: 399–412, 2004.

39. **Sato AY**, **Richardson D**, **Cregor M**, **Davis HM**, **Au ED**, **McAndrews K**, **Zimmers TA**, **Organ JM**, **Peacock M**, **Plotkin LI**, **Bellido T**. Glucocorticoids induce bone and muscle atrophy by tissue-specific mechanisms upstream of E3 ubiquitin ligases. *Endocrinology* 158: 664–677, 2017.

40. **Schakman O**, **Kalista S**, **Barbé C**, **Loumaye a**, **Thissen JPP**. Glucocorticoid-induced skeletal muscle atrophy. *Int J Biochem Cell Biol* 45: 2163–2172, 2013.

41. **Schiaffino S**, **Reggiani C**. Fiber types in mammalian skeletal muscles. *Physiol Rev* 91: 1447–531, 2011.

42. **Sher J**, **Cardasis C**. SKELETAL MUSCLE FIBER TYPES IN the ADULT MOUSE. *Acta Neurol Scand* 54: 45–56, 1976.

43. **Shpilberg Y**, **Beaudry JL**, **D’Souza A**, **Campbell JE**, **Peckett A**, **Riddell MC**. A rodent model of rapid-onset diabetes induced by glucocorticoids and high-fat feeding. *Dis Model Mech* 5: 671–680, 2012.

44. **Tallis J**, **James RS**, **Seebacher F**. The effects of obesity on skeletal muscle contractile function. *J Exp Biol* 221: jeb163840, 2018.

45. **Trappe S**, **Trappe T**, **Gallagher P**, **Harber M**, **Alkner B**, **Tesch P**. Human single muscle fibre function with 84 day bed-rest and resistance exercise. *J Physiol* 557: 501–513, 2004.

46. **Vyas S**, **Rodrigues AJ**, **Silva JM**, **Tronche F**, **Almeida OFX**, **Sousa N**, **Sotiropoulos I**. Chronic Stress and Glucocorticoids: From Neuronal Plasticity to Neurodegeneration. *Neural Plast* 2016: 1–15, 2016.

47. **Waddell DS**, **Baehr LM**, **van den Brandt J**, **Johnsen SA**, **Reichardt HM**, **Furlow JD**, **Bodine SC**. The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. *AJP Endocrinol Metab* 295: E785–E797, 2008.

48. **Wester VL**, **Staufenbiel SM**, **Veldhorst M a B**, **Visser J a**, **Manenschijn L**, **Koper JW**, **Klessens-Godfroy FJM**, **van den Akker ELT**, **van Rossum EFC**. Long-term cortisol levels measured in scalp hair of obese patients. *Obesity* 00: 1–3, 2014.

49. **Wilson JM**, **Loenneke JP**, **Jo E**, **Wilson GJ**, **Zourdos MC**, **Kim J-S**. The Effects of Endurance, Strength, and Power Training on Muscle Fiber Type Shifting. *J Strength Cond Res* 26: 1724–1729, 2012.

50. **Wolfe RR**. The underappreciated role of muscle in health and disease 1 Ϫ 3. : 475–482, 2018.

51. **Zoico E**, **Di Francesco V**, **Guralnik JM**, **Mazzali G**, **Bortolani A**, **Guariento S**, **Sergi G**, **Bosello O**, **Zamboni M**. Physical disability and muscular strength in relation to obesity and different body composition indexes in a sample of healthy elderly women. *Int J Obes* 28: 234–241, 2004.

# Figure Legends

**Figure 1. Obese-Dexamethasone Treated Mice Lost Significant Muscle Strength**

Grip strength (N) in lean (A) and obese (B) male mice over the course of six weeks of dexamethasone treatment. n=4-8 per group. Data collected by Innocence Harvey. Force generated by nerve stimulation (C) and by direct muscle stimulation (gastrocnemius; D) in lean and obese mice treated with dexamethasone for 15-21 days. Force plotted relative to whole muscle cross-sectional area (gastrocnemius; E-F). Asterisks indicate significant interaction between diet and dexamethasone treatment by two-way ANOVA (n=5-8 per group).

**Figure 2. Obese-Dexamethasone Treated Mice had Reduced Lean Mass, Muscle Weights, and Type II Fiber CSA.**

Lean mass determined via EchoMRI (A) and muscle weights (B) in lean and obese mice following 6 weeks of dexamethasone treatment (n=8-22 per group). Data collected by Innocence Harvey. Muscle weights (gastrocnemius; C) and cross-sectional area (gastrocnemius; D) in lean and obese mice treated with dexamethasone for 15-21 days (n=5-8 per group). H&E stained section of muscles(quadriceps; E) from mice treated with vehicle (water) or dexamethasone for six weeks. Average fiber cross-sectional area (F) averaged from 200 fibers per section (quadriceps; n=4 mice per group). NADH-NBT stained section of muscles (quadriceps; G) from mice treated with vehicle (water) or dexamethasone for six weeks. Percent of slow-oxidative or Type I fibers to total fibers (H; n=4 sections per group). Average fiber cross-sectional area separated by NADH-NBT staining density with dark fibers indicating slow-oxidative or Type I muscle fibers (quadriceps; I). Asterisks indicate significant interaction between diet and dexamethasone treatment by two-way ANOVA.

**Figure 3. Short-term Dexamethasone Treatment Induced Muscle Degradation Transcripts unlike Chronic or Long-Term Treatment**

Relative atrogene (*Fbxo32, Trim63, Foxo1* and *Foxo3*) expression in C2C12 myotubes treated with 250 nM dexamethasone for 2, 4, 8,12, or 24 hours or left untreated(A). After treatment, cells were homogenized and prepared for RNA extraction.

Atrogene expression in mice treated for either 72 hours, one week, or two weeks with vehicle(water) or 1mg/kg/d dexamethasone (B). RNA was extracted from the mice (quadriceps) treated for six weeks with vehicle (water) or dexamethasone. Asterisks indicate significant interaction between diet and dexamethasone treatment by two-way ANOVA. n=8 per group.

**Figure 4. Dexamethasone Treatment Induced Insulin Resistance** Blood glucose values taken from the tail vein in lean and obese male mice after a 6-hour fast and two weeks of dexamethasone or vehicle (water) treatment (A). Asterisks indicate significant interaction between diet and dexamethasone treatment by two-way ANOVA. n=4 mice per group. Glucose values after insulin administration at time 0, following a 6-hour fast (B). Insulin was given via intraperitoneal injection at .75g/kg lean mass for lean mice and 1.5g/kg for obese mice.n=4 mice per group.Asterisks indicate significant interaction between diet and dexamethasone treatment by two-way ANOVA

**Table 1. Body Weight, Fat Mass and Food and Treatment Intake**

Body weight was measured weekly on a digital scale as well as fat mass via EchoMRI. Percent fat mass was calculated as an average of the ratio of total fat mass to total body weight per mouse. Asterisks indicate significant interaction between diet and dexamethasone treatment by two-way ANOVA. n=3-4 per group. Average food and caloric intake represent the grams and kcal of NCD or HFD consumed eaten per mouse per day. n=3-4 mice per group. Vehicle(water) and dexamethasone-water were also measured weekly. Asterisks indicate significant interaction between diet and dexamethasone treatment by two-way ANOVA.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **NCD, Vehicle(Water)** | **NCD, Dexamethasone** | **HFD, Vehicle(Water)** | **HFD, Dexamethasone** |
| Average Body Weight at sacrifice (g) | 31.5 ± 7.5 | 29.2 ± 1.5 | 46.5 ± 9.8 | 34.2 ± 1.6 \* |
| Average Fat Mass at sacrifice (g) | 3.1 ± 0.6 | 3.6 ± 0.5 | 16.0 ± 1.3 | 11.6 ± 1.6 \* |
| Percent Fat Mass at sacrifice | 9.8 ± 1.7 | 12 ± 1.2 | 34 ± 2.0 | 33 ± 3.2 |
| Average Food Intake per mouse per day (g) | 3.5 ± 0.09 | 3.7 ± 0.21 | 2.1 ± 1.0 | 3.6 ± .31 |
| Average Calorie Intake per mouse per day (kcal) | 10.1 ± 0.26 | 10.8 ± 0.61 | 9.9 ± 4.7 | 17.0 ± 1.5 \* |
| Average Liquid Intake per mouse per day (mL) | 6.2 ± 1.1 | 7.4 ± 0.91 | 4.2 ± 0.43 | 11.3 ± 3.7 |

**Table 2. List of Primers**

Key atrophy transcripts, *Fbxo32* and *Trim63*, (Atrogin-1 and MuRF1 respectively) and their upstream regulators, *Foxo1* and *Foxo3. Rplp13* was used a control gene.

|  |  |  |
| --- | --- | --- |
| **Gene** | **Forward 5’-3’ Sequence** | **Reverse 5’-3’ Sequence** |
| *Fbxo32* | CTTCTCGACTGCCATCCTGG | GTTCTTTTGGGCGATGCCAC |
| *Trim63* | GAGGGCCATTGACTTTGGGA | TTTACCCTCTGTGGTCACGC |
| *Foxo1* | AGTGGATGGTGAAGAGCGTG | GAAGGGACAGATTGTGGCGA |
| *Foxo3* | AAACGGCTCACTTTGTCCCA | ATTCTGAACGCGCATGAAGC |
| *Rplp13* | GCGGATGAATACCAACCCCT | CCTGGCCTCTCTTGGTCTTG |